LGALS1 and myeloid neoplasm: Collectively, these results highlight galectin-1 as a central pathological mediator in myeloid malignancies, a promising biomarker, and a therapeutic target that may alter the disease course, which is not possible to achieve for the majority of patients using currently available medical therapies.